| Literature DB >> 29449867 |
Shahida Khan1, Ashraf Ali1, Sarah Khan2, Ahmed Bakillah3, Ghazi Damanhouri1, Aziz Khan1, Ahmad Makki1, Ibtehal AlAnsari1, Naheed Banu4.
Abstract
Background: Liver dysfunction is a topic of global concern with many advancing therapies being researched. Though vitamin D takes a center place, other therapies especially nutritional are also gaining ground. Vitamin D has gone beyond its role in skeletal disorders by showcasing its associations in other metabolic dysfunctions too. Result: Epidemiological evidences show a correlation between the status of vitamin D and different forms of cancer. Vitamin D receptors and alterations in gene expression appear decisive in the development of chronic liver disorders. Nutritional status therefore plays a significant role in avoiding the complications related to liver dysfunctions, making it mandatory in maintaining vitamin D sufficiency in the body. Therapies with omega-3 fatty acids, antioxidants, amino acids, steroids also render benefits which could be further explored. Recent research on the progression of certain forms of liver cancer using vitamin D analogs like Seocalcitol EB 1089 has shown good promise.Entities:
Keywords: Anti-inflammatory; Current therapies; Liver disorders; Vitamin D
Year: 2018 PMID: 29449867 PMCID: PMC5807831 DOI: 10.1186/s12986-018-0251-5
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Some of the genes and their functions/organs regulated by vitamin D
| Gene | Target Organ | Regulation | Function of genes involved |
|---|---|---|---|
| PTH | Parathyroid gland | down | Induces Cyp27B1 and inhibit 24-hydroxylation, increase calcitriol synthesis |
| Cyp24A1 (VD-24-hydroxylase) | kidney | up | Inactivates calcitriol to 1,24,25(OH)3D3, which can be oxidized to calcitriol acid for secretion |
| Interleukin −12(IL-12) | Innate Immune Cell | down | Restrain Th1 activation by limiting IL-12 |
| FGF15 (FGF19 for humans) | Ileum | up | Suppresses bile acid synthesis in hepatocytes through induction of SHP |
| Cyp27B1 (VD-1alpha-hydroxylase | kidney | down | Restrains VD synthesis by feedback inhibition |
| Cyp3A4 | liver | Catabolizes bile acid and xenobiotics, | |
| SULT2A1 | liver | up | Detoxification of steroids, xenobiotics, and bile acid for secretion |
| MRP3 | liver | up | Transportations of range of substrates such as anti-cancer drugs and bile acid |
| Cathelicidin | intestine | up | immune defense against invasive bacterial infection |
| ASBT | Ileum | up | Enhances bile acid re-adsorption from ileum, which may restrain bile acid synthesis in the liver via feedback inhibition |
| Calbindin D9K | Intestine, Kidney | up | Transport of calcium across the enterocytes |
| TRPV6 | intestine | up | Help in calcium absorption in the intestine |
| Defensin beta 2 | Immune cells | up | Exhibits potent antimicrobial activity against Gram-negative bacteria and Candida, but not against Gram-positive |
| FasL/CD95L | Immune cells | down | Reduces apoptosis |
| E-cadherin | skin | down | Restrains epithelial to mesenchymal transition |
| Interferon-gamma | T cells | up | Restrains immunity |
Clinical and non-clinical effect of Vitamin D on various target organs
| Function | Target Organ/Function | Reference |
|---|---|---|
| Inhibits in vitro HCV replication in a dose-dependent manner | Liver | [ |
| Vitamin D supplementation may improve SVR rate in HCV among various genotypes | Liver | [ |
| Low vitamin D level leads to non-responsiveness to interferon based treatment | Liver | [ |
| Vitamin D deficiency causes downregulation of 25-hydroxylase CYP27A1 in, liver resulting in increased fibrosis and low SVR | Liver | [ |
| Deficiency causes increase in fibrosis and inflammation in liver | Liver | [ |
| Supplementation/phototherapy improves liver histology in preclinical studies of NAFLD | Liver[NAFLD] | [ |
| Supplementation prevents liver fibrosis in preclinical studies | Liver[NAFLD] | [ |
| Low vitamin D level causes severe steatosis, inflammation and fibrosis | Liver[NAFLD] | [ |
| Vitamin D deficiency causes increased hepatic expression of TLR2, TLR4 and TLR9, which are implicated in NAFLD pathogenesis | Liver[NAFLD] | [ |
| Vitamin D increases Ca and PO4 absorption from small intestine | Calcium and Bone | [ |
| It Suppresses PTH secretion and Induces osteoclast maturation | Calcium and Bone | [ |
| Normal vitamin D level lowers prevalence of metabolic syndrome by 67% | Pancreatic functions | [ |
| Supplementation improves insulin sensitivity and lowers risk of developing type 2 diabetes | Pancreatic functions | [ |
| Vitamin D deficiency increases chances of insulin resistance | Pancreatic functions | [ |
| Impaired pancreatic β-cell function in cases of low vitamin D level | Pancreatic functions | [ |
| Low level of vitamin D decreases macrophage TLR response and increase chances of TB infection | Innate Immunity | [ |
| Vitamin D is essential for NK cell development and function | Innate Immunity | [ |
| Vitamin D Inhibits proliferation of Th1 lymphocytes | Adaptive Immune System | [ |
| Supplementation decreases risk of developing MS in women and type 1 diabetes in children | Adaptive Immune System | [ |
| Low vitamin D level increases risk of | Immunity | [ |
| Normal Vitamin D level decreased population incidence of autoimmune diseases such as MS | Immunity | [ |
| Higher 25(OH)D levels associated with lower incidence of colorectal adenoma | Carcinogenesis | [ |
| Sunlight exposure associated with reduced risk of NHL | Carcinogenesis | [ |
| Vitamin D decreased risk of colon, breast and prostate cancer | Carcinogenesis | [ |
| Vitamin D deficiency is associated with bone weakness and painful crises | SCD | [ |
| vitamin D deficiency and its potential association with acute pain in SCD | SCD | [ |
SVR Sustained Virological Response, NAFLD Non-alcoholic fatty liver disease, TLR Toll like Receptor, PTH Parathyroid Hormone, MS Multiple Sclerosis, NHL Non-Hodgkin lymphoma, SCD Sickle Cell Disease
Recent published trials on Vitamin D supplementation and HCC
| Trial | Results | Reference |
|---|---|---|
| Association of Serum 25-Hydroxyvitamin D concentrations with certain circulating blood parameters in Cirrhotic Patients. | Though supplementation of vitamin D considerably enhances serum levels of 25(OH) D, no significant effect either on liver function tests and fibrosis or on PTH and mineral metabolites was observed. | [ |
| Gene polymorphisms of the vitamin d receptor may prove a risk factor for development of HCC. | In chronic hepatitis C patients, the role of VDR ApoI polymorphism is crucial in the development of HCC | [ |
| 25-hydroxyvitamin D deficiency as a prognostic marker in patients with HCC. | 25(OH) D3 is a marker metabolite for poor consequences and its deficiency is associated with advanced progression of HCC. | [ |
| Association between circulating vitamin D levels and the risk of developing HCC amongst Europeans. | There is an inverse association between the 25(OH) D serum concentrations and the risk of HCC. | [ |
| Mechanistic role of 1, 25(OH) 2D3 in the progression of hepatocellular carcinoma. | Decreased expression of HDAC2 and increased expression of p21 (WAF1/Cip1), repressed the progression of HCC on administration of 1, 25(OH) 2D3 suggesting a therapeutic role of the vitamin in potential drug developments. | [ |
| Tapping the 25(OH) D-induced cell growth inhibition potential for future targeted therapy in HCC patients. | 25(OH)D and CYP27B1 gene transfection therapy could well be targeted for future HCC management studies | [ |
| Effect of SNPs in VDR and DBP genes on HBV linked HCC risk amongst Chinese. | Polymorphisms of VDR rs2228570 and DBP rs7041 may be responsible for an increased susceptibility to HBV-related HCC amongst Chinese residents. | [ |
| Association of vitamin D and cytokine production in HCC | Up-regulation of p27(kip1) expression in immune cells and reduction in the production of cytokines may contribute towards the inhibition of HCC progression on administration of vitamin D | [ |
| Use of vitamin D, IL-6, and IL-17 concentrations as potential biomarkers in HCC patients for a more favorable prognosis | Vitamin D and the cytokines IL-6and IL-7 could be additionally used as prognostic markers in HCV and cirrhotic patients to suppress the development of HCC in them. | [ |
| Effect of vitamin D supplementation on levels of CYP24A1 mRNA in hepatocellular carcinoma cell lines. | In-vitro supplementation of 1, 25(OH) (2) D (3) results in marked increases of CYP24A1 mRNA expression in few, though not all, human HCC lines. | [ |